Precision receives US patent related to engineered meganucleases

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

- Advertisement -

Precision BioSciences has received US patent which covers claims related to methods of cleaving a target DNA site in a cell using an engineered meganuclease. These methods are broadly utilized as a part of Precision’s DNE genome engineering technology, the company said. Precision announced in October 2011 that it has asserted the ‘867 Patent against Cellectis in a suit pending in the US District Court for the Eastern District of North Carolina.

Precision scientific development vice president said the claimed methods include the use of engineered features that are a key aspect of Precision’s award-winning DNE approach to genome engineering.

Latest stories

Previous article

Vanda reports positive data of tasimelteon in Non-24-Hour Disorder

Next article

Orexo announces termination of OX-CLI and OX-ESI programs

Related stories

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »

MORE STORIES